Evident Vascular Announces Scientific Advisory Board and New Board Member

30 Oct 2023
www.biospace.com
Executive Change
Scientific Advisory Board includes clinical experts in interventional cardiology, interventional radiology and vascular surgery Bruce Shook, seasoned medtech executive and entrepreneur, joins Board of Directors SAN JOSE, Calif.--(BUSINESS WIRE)-- Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors. “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board. Their collective expertise and experience innovating new peripheral vascular disease procedures and technologies will be invaluable as we develop a best-in-class IVUS platform designed to meet the specific needs of the interventionalist, enabling them to provide the best patient care,” said Evident Vascular CEO and co-founder, Howard Rosen. “We are also pleased to welcome Bruce Shook to the Evident Vascular Board of Directors. Bruce is an accomplished CEO and entrepreneur, with a long and successful career building companies and bringing new medical technologies to market.” “IVUS can play a critical role in the diagnosis and treatment of peripheral disease. There is significant clinical need for higher quality imaging to enable better image interpretation without compromising workflow and catheter performance,” said S. Jay Mathews, MD, MS, FACC, FSCAI, Director, Cardiac Catheterization Laboratory, Manatee Memorial Hospital and VIVA/VEINS 2023 Faculty and Scientific Committee Member. "An AI-enabled platform may help address the interventionalist’s clinical needs and creates the potential to broaden adoption of IVUS in peripheral and eventually coronary vascular procedures. I’m pleased to partner with the Evident team and this outstanding group of thought leaders to support the company’s efforts.” Evident Vascular Scientific Advisory Board: Ehrin Armstrong, MD, MSc, FACC, FSCAI, FSVM, Advanced Heart and Vein Center Venita R. Chandra, MD, Stanford University Medical Center Paul Gagne, MD, FACS, DFSVS, RVT, Vascular Care Connecticut Mark J. Garcia, MD, FSIR, FACR, Endovascular Consultants S. Jay Mathews, MD, MS, FACC, FSCAI, Manatee Memorial Hospital Mahmood K. Razavi, MD, MS, FSIR, FSVM, St Joseph Heart & Vascular Center and Vascular and Interventional Specialists of Orange County Inc John Rundback, MD, FSIR, FSVM, FAHA, Holy Name Medical Center and Advanced Interventional & Vascular Services, LLP Peter Schneider, MD, UCSF Health Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, Beth Israel Deaconess Medical Center “Evidence supports the use of IVUS in the management of peripheral vascular interventions to improve clinical outcomes and procedural efficiencies,” said Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, Director of Vascular Intervention, Beth Israel Deaconess Medical Center and Board Director, VIVA “By developing its IVUS platform from the ground up initially for peripheral vascular interventions, Evident Vascular’s device will help to ensure that peripheral patients are treated at the right time, with the most appropriate and optimal intervention.” The company also announced the addition of Bruce Shook as an independent director, joining Howard Rosen, Patrick Phillips, Ph.D., CTO and Co-founder of Evident Vascular, Danielo Piazza, CPO and Co-founder of Evident Vascular, Justin Klein, MD, JD, and Cynthia Yee of Vensana Capital® on Evident Vascular’s Board of Directors. Bruce Shook, former CEO of Intact Vascular and Vesper Medical, said, “Peripheral interventions are already the fastest growing segment of IVUS, even with legacy technology built for coronary procedures. Evident Vascular is developing the first IVUS platform designed for peripheral interventions, with enhanced ease of use and improved image quality. I look forward to working with the Board and the leadership team to help bring this innovative technology to market and significantly expand the use of IVUS.” About Evident Vascular Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions. For more information, visit the company’s website and follow us on LinkedIn. Evident Vascular™ and Evident™ are trademarks of Evident Vascular, Inc. Vensana Capital® is a registered trademark of Vensana Capital Management, LLC. This press release contains “forward-looking statements” concerning the development of Evident Vascular's products, the benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Evident Vascular undertakes no obligation to update any forward-looking statements for any reason.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.